There's a good way and a bad way for biotech companies to deliver revenue growth.
The good way is to convince doctors to prescribe a drug more frequently, thereby increasing the volume of drug sold.
The bad way is to to offset declines in the volume, or amount, of drug sold.
It should be obvious why volume-based revenue growth is preferred over growth driven by price increases. The former means user demand for a drug and its market share are...
More